CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline

BClinical — prospective trial or retrospective cohort study

CCase study — single case report or small case series

DPreclinical — in vitro or animal model data

EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

	Predictive	Diagnostic	Prognostic	Functional	Predispos.	Oncogenic
BCR::ABL1	323	11
BRAF	186	4	26	2		1
EGFR	248		12	3		2
EML4::ALK	64
ERBB2	142		2
FLT3	55	2	21
KIT	102	3	7
KRAS	159	4	24			4
PIK3CA	156		16	4
PTEN	53	1	3	1	2	1
TP53	52		40	100	2
VHL	5	2	3		635	15

Predictive:Links a variant to treatment response or resistance

Diagnostic:Supports or refutes a specific disease diagnosis

Prognostic:Informs disease progression or clinical outcome

Functional:Characterises the biological effect of a variant

Predisposing:Germline variant associated with cancer predisposition

Oncogenic:Characterises the variant's role in oncogenesis

Level	Gene	Variant	Type	Direction	Significance	Disease	Drugs	Source
C	BCOR::CCNB3	Fusion	Diagnostic	Supports	Positive	Kidney Clear Cell Sarcoma		Wong et al., 2018
C	BCOR::CCNB3	Fusion	Diagnostic	Supports	Positive	Kidney Clear Cell Sarcoma		Han et al., 2020
C	BCOR::CCNB3	Fusion	Diagnostic	Supports	Positive	Kidney Clear Cell Sarcoma		Argani et al., 2017
C	v::NUTM1	Fusion	Diagnostic	Supports	Positive	NUT Midline Carcinoma		Dickson et al., 2018
A	PIK3CA	R88Q	Predictive	Supports	Sensitivity/Response	Her2-receptor Negative Breast Cancer	Fulvestrant,Capivasertib	Turner et al., 2023
C	BCR::NTRK2	Fusion	Predictive	Does Not Support	Sensitivity/Response	Ganglioglioma	Entrectinib	Desai et al., 2022
B	MTOR	Mutation OR PIK3CA Mutation OR PTEN Mutation OR AKT1 Mutation OR AKT2 Mutation	Predictive	Supports	Sensitivity/Response	Solid Tumor	Sapanisertib	Subbiah et al., 2024
D	IFNGR1	Loss	Predictive	Supports	Resistance	Melanoma	Ipilimumab	Gao et al., 2016
C	IGH::IL3	Fusion	Diagnostic	Supports	Positive	B-lymphoblastic Leukemia/lymphoma With IGH::IL3 Fusion		Grimaldi et al., 1989
C	FUS::TFCP2	Fusion AND ALK Exon 2-18 Deletion	Predictive	Supports	Sensitivity/Response	Spindle Cell Rhabdomyosarcoma	Alectinib	Csizmok et al., 2024
D	FUS::DDIT3	Fusion	Diagnostic	Supports	Positive	Myxoid Liposarcoma		Trautmann et al., 2017
B	FGFR1	Amplification	Predictive	Supports	Sensitivity/Response	Breast Cancer	Erdafitinib	Gong et al., 2024
B	FGFR1	Amplification	Predictive	Supports	Sensitivity/Response	Breast Cancer	Dovitinib	Musolino et al., 2017
B	FGFR1	Amplification	Predictive	Does Not Support	Sensitivity/Response	Breast Cancer	Sunitinib	Calfa et al., 2024
D	FGFR1	Amplification	Predictive	Supports		Breast Cancer	Lucitanib,Rogaratinib	Sánchez-Guixé et al., 2022
B	STK11	Mutation	Predictive	Does Not Support	Sensitivity/Response	Lung Non-small Cell Carcinoma	Vistusertib	Middleton et al., 2025
D	EWSR1::FLI1	Fusion	Predictive	Supports	Sensitivity/Response	Ewing Sarcoma	HCI-2509	Sankar et al., 2014
C	EWSR1::NR4A3	Fusion OR TAF15::NR4A3 Fusion	Predictive	Supports	Sensitivity/Response	Extraskeletal Myxoid Chondrosarcoma	Trabectedin	Morioka et al., 2016
D	STK11	Loss	Predictive	Supports	Sensitivity/Response	Pancreatic Ductal Adenocarcinoma	Roflumilast	Zhang et al., 2024
B	NFE2L2	Mutation OR KEAP1 Mutation OR CUL3 Mutation	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Platinum Doublet	Jeong et al., 2020
D	NQO1	Overexpression	Predictive	Supports	Sensitivity/Response	Pancreatic Ductal Adenocarcinoma	NSC84167	Dai et al., 2021
D	KEAP1	Mutation	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	NSC84167	Dai et al., 2021
C	HEY1::NCOA2	Fusion	Predictive	Supports	Sensitivity/Response	Mesenchymal Chondrosarcoma	Trabectedin	Morioka et al., 2016
C	FUS::NFATC2	Fusion	Diagnostic	Supports	Positive	Round Cell Sarcoma With EWSR1-non-ETS Fusion		Perret et al., 2020
C	RET	M918T	Predisposing	Supports	Predisposition	Medullary Thyroid Carcinoma		Romei et al., 2018
C	TP53	R273C OR TP53 G245S OR TP53 R213*	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Vorinostat,Pazopanib	Fu et al., 2015
C	BRAF	V600	Predictive	Supports	Sensitivity/Response	Histiocytic Sarcoma	Dabrafenib/Trametinib Regimen	Tan et al., 2025
C	BRAF	V600E AND BRAF V600M	Predictive	Supports	Sensitivity/Response	Melanoma	Dabrafenib	Ponti et al., 2012
B	KRAS	Exon 2 Mutation	Predictive	Does Not Support	Sensitivity/Response	Colorectal Cancer	Regorafenib Anhydrous	Sartore-Bianchi et al., 2014
E	EGFR	T790M	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Staurosporine	Ai et al., 2014
B	PGR	Expression	Predictive	Does Not Support	Sensitivity/Response	Breast Cancer	Tamoxifen	Patani et al., 2013
B	PTEN	Loss	Predictive	Supports	Resistance	Breast Cancer	Trastuzumab	Dillon et al., 2014
D	KRAS	G12V	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Palbociclib	Puyol et al., 2010
B	FGFR1	Expression	Prognostic	Supports	Poor Outcome	Head And Neck Squamous Cell Carcinoma		Ipenburg et al., 2016
B	MDM2	EXPRESSION	Predictive	Supports	Resistance	Malignant Pleural Mesothelioma	Pemetrexed,Cisplatin	Walter et al., 2015
B	TOP1	Amplification	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Irinotecan	Nygård et al., 2014
B	AGR2	EXPRESSION	Predictive	Supports	Resistance	Breast Cancer	Tamoxifen	Hrstka et al., 2013
B	ERBB2	Amplification	Predictive	Does Not Support	Resistance	Colorectal Cancer	Cetuximab,Capecitabine,Oxaliplatin	Sclafani et al., 2013
D	EGFR	VIII	Predictive	Supports	Sensitivity/Response	Brain Glioma	Nimotuzumab	Nitta et al., 2016
B	KIT	RS3733542	Predictive	Supports	Sensitivity/Response	Acute Myeloid Leukemia	Selumetinib	Jain et al., 2014
B	KRAS	G12V	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Selumetinib,Docetaxel	Jänne et al., 2015
D	HSPH1	NUCLEAR EXPRESSION	Predictive	Supports	Sensitivity/Response	Gastric Adenocarcinoma	Cisplatin,Fluorouracil	Kimura et al., 2016
B	ECSCR	EXPRESSION	Predictive	Does Not Support	Sensitivity/Response	Cancer	Angiogenesis Inhibitor	Pircher et al., 2016
B	ROBO4	EXPRESSION	Predictive	Does Not Support	Sensitivity/Response	Cancer	Angiogenesis Inhibitor	Pircher et al., 2016
D	KRAS	Mutation	Predictive	Supports	Resistance	Colorectal Cancer	Ixazomib	Chattopadhyay et al., 2015
C	KDR	R961W	Predictive	Supports	Sensitivity/Response	Colorectal Adenocarcinoma	Regorafenib Anhydrous	Loaiza-Bonilla et al., 2016
D	GNA11	Mutation	Predictive	Supports	Sensitivity/Response	Uveal Melanoma	JQ1	Ambrosini et al., 2015
C	CD72::ROS1	Fusion	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Ceritinib	Subbiah et al., 2016
D	SIRT1	Overexpression	Predictive	Supports	Resistance	Pancreatic Cancer	Niacinamide	Stenzinger et al., 2013
B	PPP1R15A	RS557806	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	FOLFIRI Regimen,Bevacizumab	Roh et al., 2016

Page 89 of 96

Previous Next